SEC Info - Aerie Pharmaceuticals Inc. - ‘10-Q’ for 6/30/22

SEC Info℠

Home

Help

Please Sign In

Aerie Pharmaceuticals Inc. – ‘10-Q’ for 6/30/22 – ‘EX-101.CAL’

On: Thursday, 8/4/22, at 6:35pm ET · As of: 8/5/22 · For: 6/30/22 · Accession #: 1337553-22-33 · File #: 1-36152

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/05/22  Aerie Pharmaceuticals Inc.        10-Q        6/30/22   65:6.6M

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.45M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     24K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
11: R1          Cover                                               HTML     71K 
12: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML    120K 
13: R3          Condensed Consolidated Balance Sheets (Unaudited)   HTML     36K 
                (Parenthetical)                                                  
14: R4          Condensed Consolidated Statements of Operations     HTML     91K 
                and Comprehensive Loss (Unaudited)                               
15: R5          Condensed Consolidated Statements of Stockholders'  HTML    117K 
                (Deficit) Equity (Unaudited)                                     
16: R6          Condensed Consolidated Statements of Cash Flows     HTML     88K 
                (Unaudited)                                                      
17: R7          The Company                                         HTML     46K 
18: R8          Significant Accounting Policies                     HTML     42K 
19: R9          Revenue Recognition                                 HTML     54K 
20: R10         Investments                                         HTML     73K 
21: R11         Fair Value Measurements                             HTML     72K 
22: R12         Inventory                                           HTML     27K 
23: R13         Property, Plant and Equipment, Net                  HTML     33K 
24: R14         Leases                                              HTML     22K 
25: R15         Accrued Expenses and Other Current Liabilities      HTML     31K 
26: R16         Debt                                                HTML     53K 
27: R17         Stock-Based Compensation                            HTML     78K 
28: R18         Commitments and Contingencies                       HTML     29K 
29: R19         Significant Accounting Policies (Policies)          HTML     39K 
30: R20         Significant Accounting Policies (Tables)            HTML     34K 
31: R21         Revenue from Contract with Customer (Tables)        HTML     34K 
32: R22         Investments (Tables)                                HTML     71K 
33: R23         Fair Value Measurements (Tables)                    HTML     71K 
34: R24         Inventory (Tables)                                  HTML     27K 
35: R25         Property, Plant and Equipment, Net (Tables)         HTML     32K 
36: R26         Accrued Expenses and Other Current Liabilities      HTML     31K 
                (Tables)                                                         
37: R27         Debt (Tables)                                       HTML     41K 
38: R28         Stock-Based Compensation (Tables)                   HTML     77K 
39: R29         The Company (Details)                               HTML     47K 
40: R30         Significant Accounting Policies - Additional        HTML     32K 
                Information (Details)                                            
41: R31         Significant Accounting Policies - Computation of    HTML     33K 
                Diluted EPS (Details)                                            
42: R32         Revenue Recognition - Narrative (Details)           HTML     65K 
43: R33         Revenue Recognition - Deferred Revenue, Noncurrent  HTML     36K 
                (Details)                                                        
44: R34         Investments - Cash, Cash Equivalents and            HTML     64K 
                Investments (Details)                                            
45: R35         Investments - Additional Information (Details)      HTML     23K 
46: R36         Fair Value Measurements - Fair Value Measurements   HTML     66K 
                (Details)                                                        
47: R37         Fair Value Measurements - Additional Information    HTML     22K 
                (Details)                                                        
48: R38         Inventory (Details)                                 HTML     31K 
49: R39         Property, Plant and Equipment, Net - Property,      HTML     40K 
                Plant and Equipment (Details)                                    
50: R40         Leases - Narrative (Details)                        HTML     35K 
51: R41         Accrued Expenses and Other Current Liabilities      HTML     32K 
                (Details)                                                        
52: R42         Debt - Narrative (Details)                          HTML     77K 
53: R43         Debt - Convertible Debt (Details)                   HTML     34K 
54: R44         Debt - Interest Expense of Convertible Notes        HTML     33K 
                (Details)                                                        
55: R45         Stock-Based Compensation - Stock-based              HTML     29K 
                Compensation Expense (Details)                                   
56: R46         Stock-Based Compensation - Additional Information   HTML     77K 
                (Details)                                                        
57: R47         Stock-Based Compensation - Stock Options Activity   HTML     64K 
                (Details)                                                        
58: R48         Stock-Based Compensation - Restricted Stock         HTML     49K 
                Activity (Details)                                               
59: R49         Stock-Based Compensation - Stock Appreciation       HTML     55K 
                Rights (Details)                                                 
60: R50         Commitments and Contingencies - Additional          HTML     52K 
                Information (Details)                                            
63: XML         IDEA XML File -- Filing Summary                      XML    112K 
61: XML         XBRL Instance -- aeri-20220630_htm                   XML   1.58M 
62: EXCEL       IDEA Workbook of Financial Reports                  XLSX    118K 
 7: EX-101.CAL  XBRL Calculations -- aeri-20220630_cal               XML    148K 
 8: EX-101.DEF  XBRL Definitions -- aeri-20220630_def                XML    508K 
 9: EX-101.LAB  XBRL Labels -- aeri-20220630_lab                     XML   1.32M 
10: EX-101.PRE  XBRL Presentations -- aeri-20220630_pre              XML    789K 
 6: EX-101.SCH  XBRL Schema -- aeri-20220630                         XSD    128K 
64: JSON        XBRL Instance as JSON Data -- MetaLinks              344±   520K 
65: ZIP         XBRL Zipped Folder -- 0001337553-22-000033-xbrl      Zip    361K

‘EX-101.CAL’ — XBRL Calculations — aeri-20220630_cal

This Exhibit is an XBRL XML File.

<?xml version="1.0" encoding="windows-1252"?>

<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://www.aeriepharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="aeri-20220630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_52752404-bf67-44b4-ba18-162a800ba3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ba6d921f-9ad6-48e9-9f96-aa06cf8e5bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_52752404-bf67-44b4-ba18-162a800ba3ef" xlink:to="loc_us-gaap_AssetsCurrent_ba6d921f-9ad6-48e9-9f96-aa06cf8e5bf0" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a49177b8-d525-4ce7-b863-f8c5563c0c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_52752404-bf67-44b4-ba18-162a800ba3ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a49177b8-d525-4ce7-b863-f8c5563c0c2d" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fe24acb6-4706-4438-9e77-5f813f4af7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_52752404-bf67-44b4-ba18-162a800ba3ef" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fe24acb6-4706-4438-9e77-5f813f4af7d3" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a83c6b0b-4d0f-41c7-a01d-066e6fe9cc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_52752404-bf67-44b4-ba18-162a800ba3ef" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a83c6b0b-4d0f-41c7-a01d-066e6fe9cc80" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_602939e9-0ba5-4d01-a8e4-0d2c171a2df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27484c87-ded3-48b6-9598-8b1c11d6d1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_602939e9-0ba5-4d01-a8e4-0d2c171a2df9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27484c87-ded3-48b6-9598-8b1c11d6d1d3" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c0f7016b-b278-4b17-b0a1-79e1a06f057f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_602939e9-0ba5-4d01-a8e4-0d2c171a2df9" xlink:to="loc_us-gaap_PreferredStockValue_c0f7016b-b278-4b17-b0a1-79e1a06f057f" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56672ae7-2402-4eea-a093-828790ea2f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_602939e9-0ba5-4d01-a8e4-0d2c171a2df9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56672ae7-2402-4eea-a093-828790ea2f12" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7afe0798-5c10-4d2a-ae21-f9a55163e919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_602939e9-0ba5-4d01-a8e4-0d2c171a2df9" xlink:to="loc_us-gaap_CommonStockValue_7afe0798-5c10-4d2a-ae21-f9a55163e919" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2c197f6f-3f07-4c4d-80b7-0b9c74eaee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_602939e9-0ba5-4d01-a8e4-0d2c171a2df9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2c197f6f-3f07-4c4d-80b7-0b9c74eaee98" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_17701ff4-1d03-4765-9e1d-c60898a5cf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_1a5dbd9e-5671-4fae-8d45-83b6a3dd42a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17701ff4-1d03-4765-9e1d-c60898a5cf4f" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_1a5dbd9e-5671-4fae-8d45-83b6a3dd42a0" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_acee4e57-e2b3-4461-9cd2-086071c79b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17701ff4-1d03-4765-9e1d-c60898a5cf4f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_acee4e57-e2b3-4461-9cd2-086071c79b71" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3986413a-efe2-4163-934a-7ab7e4c944fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17701ff4-1d03-4765-9e1d-c60898a5cf4f" xlink:to="loc_us-gaap_LiabilitiesCurrent_3986413a-efe2-4163-934a-7ab7e4c944fb" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_394fe480-f518-4194-be80-7693ee24a5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17701ff4-1d03-4765-9e1d-c60898a5cf4f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_394fe480-f518-4194-be80-7693ee24a5ab" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_15f6e181-62c6-42d5-b056-639fff776a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_17701ff4-1d03-4765-9e1d-c60898a5cf4f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_15f6e181-62c6-42d5-b056-639fff776a62" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6da02a46-802c-4b54-bcbd-0908aaf6b10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5c8d9e10-90ef-43c7-a27d-d54af40bbfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6da02a46-802c-4b54-bcbd-0908aaf6b10c" xlink:to="loc_us-gaap_InventoryNet_5c8d9e10-90ef-43c7-a27d-d54af40bbfbb" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ce264985-95de-44c1-8b5a-1b0fcfe39eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6da02a46-802c-4b54-bcbd-0908aaf6b10c" xlink:to="loc_us-gaap_ShortTermInvestments_ce264985-95de-44c1-8b5a-1b0fcfe39eaf" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8886840e-43dd-4a9b-9562-3a8f8d8b3d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6da02a46-802c-4b54-bcbd-0908aaf6b10c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8886840e-43dd-4a9b-9562-3a8f8d8b3d53" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_612e9b31-ea3a-4045-adfd-c6ef987a944f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6da02a46-802c-4b54-bcbd-0908aaf6b10c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_612e9b31-ea3a-4045-adfd-c6ef987a944f" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_90ac1d85-9eaf-40f9-b90f-ec3708b7c1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6da02a46-802c-4b54-bcbd-0908aaf6b10c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_90ac1d85-9eaf-40f9-b90f-ec3708b7c1b5" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_LicensingReceivable_11695cf2-3821-4c9a-abfa-0b03f05902ca" xlink:href="aeri-20220630.xsd#aeri_LicensingReceivable"/>

<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6da02a46-802c-4b54-bcbd-0908aaf6b10c" xlink:to="loc_aeri_LicensingReceivable_11695cf2-3821-4c9a-abfa-0b03f05902ca" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b519c6c3-8767-411e-9a5d-dbaac3584451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3ad5e90e-a0ce-4658-893b-68f96ac53aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b519c6c3-8767-411e-9a5d-dbaac3584451" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3ad5e90e-a0ce-4658-893b-68f96ac53aa5" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2c9efd78-94a1-43cc-868c-3a93f4492e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b519c6c3-8767-411e-9a5d-dbaac3584451" xlink:to="loc_us-gaap_AccountsPayableCurrent_2c9efd78-94a1-43cc-868c-3a93f4492e18" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4248fcdc-82f9-41cd-82fe-82c0e0976088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b519c6c3-8767-411e-9a5d-dbaac3584451" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4248fcdc-82f9-41cd-82fe-82c0e0976088" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a61a8561-ee54-4a92-9eb8-436265acfbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_05571e6c-ed44-406c-9c83-cecd5c579fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a61a8561-ee54-4a92-9eb8-436265acfbb9" xlink:to="loc_us-gaap_Liabilities_05571e6c-ed44-406c-9c83-cecd5c579fae" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_da1a7a80-9c48-4b19-bdb8-6d61f27de6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a61a8561-ee54-4a92-9eb8-436265acfbb9" xlink:to="loc_us-gaap_StockholdersEquity_da1a7a80-9c48-4b19-bdb8-6d61f27de6f2" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_264c4197-0fb0-4ed9-a73b-69053ab2f1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a61a8561-ee54-4a92-9eb8-436265acfbb9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_264c4197-0fb0-4ed9-a73b-69053ab2f1cd" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="aeri-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4594b32d-d197-45c4-b4d4-a2daff2dfbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9f0168f1-df18-40f5-91d9-c5f6bfdcee4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4594b32d-d197-45c4-b4d4-a2daff2dfbd0" xlink:to="loc_us-gaap_CostsAndExpenses_9f0168f1-df18-40f5-91d9-c5f6bfdcee4e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7933860d-52c5-4ac5-92cb-fe447210d90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4594b32d-d197-45c4-b4d4-a2daff2dfbd0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7933860d-52c5-4ac5-92cb-fe447210d90a" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_178817d7-cfc4-4570-80f0-9ffa5bf82aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6ef89701-8b23-49d0-b82f-1cc6309e123a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_178817d7-cfc4-4570-80f0-9ffa5bf82aeb" xlink:to="loc_us-gaap_OperatingIncomeLoss_6ef89701-8b23-49d0-b82f-1cc6309e123a" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ca7749bb-20e6-47a1-8294-285375d8d3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_178817d7-cfc4-4570-80f0-9ffa5bf82aeb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ca7749bb-20e6-47a1-8294-285375d8d3d8" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_49d527da-eae6-4fee-99da-d3b0103b47f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2056dd71-307e-46b1-bf76-0cab92f2a1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_49d527da-eae6-4fee-99da-d3b0103b47f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2056dd71-307e-46b1-bf76-0cab92f2a1df" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_68ead2a4-085e-4d6e-9c69-681f4d20fecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_49d527da-eae6-4fee-99da-d3b0103b47f7" xlink:to="loc_us-gaap_NetIncomeLoss_68ead2a4-085e-4d6e-9c69-681f4d20fecf" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f122134c-131c-4d62-a341-9e0ad8132bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_08d7957d-9470-40e8-963a-1f9e33def406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f122134c-131c-4d62-a341-9e0ad8132bd3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_08d7957d-9470-40e8-963a-1f9e33def406" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d212f703-12a9-44b1-bcef-6c3bfa3199ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f122134c-131c-4d62-a341-9e0ad8132bd3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d212f703-12a9-44b1-bcef-6c3bfa3199ae" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_182ac276-83fe-47a9-a1e3-6ac352f3d9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f122134c-131c-4d62-a341-9e0ad8132bd3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_182ac276-83fe-47a9-a1e3-6ac352f3d9d8" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b5bb8d60-b95c-45ba-a12d-0b3f4147426a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_92392147-13d1-4784-bcfe-da687a1dc684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b5bb8d60-b95c-45ba-a12d-0b3f4147426a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_92392147-13d1-4784-bcfe-da687a1dc684" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_891a8ee5-6c44-4347-a4db-14bdb95aebd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b5bb8d60-b95c-45ba-a12d-0b3f4147426a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_891a8ee5-6c44-4347-a4db-14bdb95aebd1" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="aeri-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d63a27-0535-4b9a-b529-776f4ed95e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d7922ac8-4e7b-4520-9ae9-90bf346f5d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d63a27-0535-4b9a-b529-776f4ed95e3e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d7922ac8-4e7b-4520-9ae9-90bf346f5d29" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e15202e0-5af4-44cb-9ef1-e4e5020b94c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d63a27-0535-4b9a-b529-776f4ed95e3e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e15202e0-5af4-44cb-9ef1-e4e5020b94c0" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_64c010a3-5590-4589-af3d-040450c8b95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35d63a27-0535-4b9a-b529-776f4ed95e3e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_64c010a3-5590-4589-af3d-040450c8b95c" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51d0a55c-d5ad-4ca6-8a04-1d5fbe89a725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_PaymentsRelatedToIssuanceOfStockForStockBasedCompensationArrangements_4be3eaf2-e1bc-437a-876b-39f4260dd9f8" xlink:href="aeri-20220630.xsd#aeri_PaymentsRelatedToIssuanceOfStockForStockBasedCompensationArrangements"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51d0a55c-d5ad-4ca6-8a04-1d5fbe89a725" xlink:to="loc_aeri_PaymentsRelatedToIssuanceOfStockForStockBasedCompensationArrangements_4be3eaf2-e1bc-437a-876b-39f4260dd9f8" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc7f3075-1d35-49fe-b70f-2768db5d4ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_NetIncomeLoss_fc7f3075-1d35-49fe-b70f-2768db5d4ca7" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cf570e77-e6b3-437b-8e1f-6f9e40e29b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_Depreciation_cf570e77-e6b3-437b-8e1f-6f9e40e29b4b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_1b4c03a3-64dc-4d44-a0b0-a2d2b1afed67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_AdjustmentForAmortization_1b4c03a3-64dc-4d44-a0b0-a2d2b1afed67" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6191d6e6-5db6-4d65-a007-8ea398c5b754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_ShareBasedCompensation_6191d6e6-5db6-4d65-a007-8ea398c5b754" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_40c04011-177d-4027-b011-2ceb563d98b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>

<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_40c04011-177d-4027-b011-2ceb563d98b1" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_f0a74bdc-6513-4710-a519-8689d94f96e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>

<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_f0a74bdc-6513-4710-a519-8689d94f96e9" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a0573923-6093-4432-83b0-8441c7cdc7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>

<link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a0573923-6093-4432-83b0-8441c7cdc7e9" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_80b463b8-156f-4a4b-8090-ac49d235ad62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>

<link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_80b463b8-156f-4a4b-8090-ac49d235ad62" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_IncreaseDecreaseinOperatingLeaseLiabilities_9f7b4d9e-b8fa-4cf6-ad56-6fdd223d98de" xlink:href="aeri-20220630.xsd#aeri_IncreaseDecreaseinOperatingLeaseLiabilities"/>

<link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_aeri_IncreaseDecreaseinOperatingLeaseLiabilities_9f7b4d9e-b8fa-4cf6-ad56-6fdd223d98de" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b595327a-0863-453f-982a-87eb3e3286e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>

<link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b595327a-0863-453f-982a-87eb3e3286e0" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d2485dbe-fa11-4630-b85c-1da1c3ee63c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>

<link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d2485dbe-fa11-4630-b85c-1da1c3ee63c1" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_IncreaseDecreaseInLicensingReceivable_3e302a1b-9c4e-47b6-8207-6b31360f258b" xlink:href="aeri-20220630.xsd#aeri_IncreaseDecreaseInLicensingReceivable"/>

<link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3535a6c8-e610-41fe-aeab-8d05a5efb9a9" xlink:to="loc_aeri_IncreaseDecreaseInLicensingReceivable_3e302a1b-9c4e-47b6-8207-6b31360f258b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3e2524a-d847-4971-ab68-f3eabfa0be8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ec1de54-45f5-43bc-83cf-5676d56d9621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3e2524a-d847-4971-ab68-f3eabfa0be8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ec1de54-45f5-43bc-83cf-5676d56d9621" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f69085a-477b-43b4-bf38-06fd525d937c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3e2524a-d847-4971-ab68-f3eabfa0be8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f69085a-477b-43b4-bf38-06fd525d937c" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c35c8931-ce13-4d72-bcd7-80461b5517d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3e2524a-d847-4971-ab68-f3eabfa0be8f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c35c8931-ce13-4d72-bcd7-80461b5517d0" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/InvestmentsCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="aeri-20220630.xsd#InvestmentsCashCashEquivalentsandInvestmentsDetails"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/InvestmentsCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_aeri_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_877a12e7-a85a-43fa-8c63-4876d80e1237" xlink:href="aeri-20220630.xsd#aeri_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_af5c0e83-7baf-49ee-a113-0820439cf289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aeri_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_877a12e7-a85a-43fa-8c63-4876d80e1237" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_af5c0e83-7baf-49ee-a113-0820439cf289" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_CashAndCashEquivalentsGrossUnrealizedLoss_92e41ddc-bae8-4a6c-bf4f-00f502e59498" xlink:href="aeri-20220630.xsd#aeri_CashAndCashEquivalentsGrossUnrealizedLoss"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aeri_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_877a12e7-a85a-43fa-8c63-4876d80e1237" xlink:to="loc_aeri_CashAndCashEquivalentsGrossUnrealizedLoss_92e41ddc-bae8-4a6c-bf4f-00f502e59498" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_becd0a62-a7e1-4a95-829b-1b295afcfdc6" xlink:href="aeri-20220630.xsd#aeri_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3d67de8a-3719-4eee-9430-1f2d2b415cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aeri_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_becd0a62-a7e1-4a95-829b-1b295afcfdc6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3d67de8a-3719-4eee-9430-1f2d2b415cdd" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9cf5e732-3725-43aa-945e-1d93c4194660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aeri_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_becd0a62-a7e1-4a95-829b-1b295afcfdc6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9cf5e732-3725-43aa-945e-1d93c4194660" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_480bed83-782e-4699-8026-3d69013510f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_148890dd-a4ed-403b-a2db-60ceee921862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_480bed83-782e-4699-8026-3d69013510f5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_148890dd-a4ed-403b-a2db-60ceee921862" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0af0dae7-c4ff-43e7-b10b-2a917be1ba73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_480bed83-782e-4699-8026-3d69013510f5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0af0dae7-c4ff-43e7-b10b-2a917be1ba73" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c14b1dc8-0fde-4571-8ea5-9849f35c918f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_480bed83-782e-4699-8026-3d69013510f5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c14b1dc8-0fde-4571-8ea5-9849f35c918f" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_96ad04a5-b727-4944-8aca-a2b06c2fc8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_986e3218-14f5-4331-891d-73a5abcf62a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_96ad04a5-b727-4944-8aca-a2b06c2fc8ba" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_986e3218-14f5-4331-891d-73a5abcf62a6" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3b0b2b21-7707-4ab1-ab32-f2389d1516f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_96ad04a5-b727-4944-8aca-a2b06c2fc8ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3b0b2b21-7707-4ab1-ab32-f2389d1516f2" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_6f958c0d-003d-41cc-b547-602e9d4f06b0" xlink:href="aeri-20220630.xsd#aeri_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5716044b-c0eb-4447-b07a-be783cefc434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aeri_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_6f958c0d-003d-41cc-b547-602e9d4f06b0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5716044b-c0eb-4447-b07a-be783cefc434" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_CashAndCashEquivalentsGrossUnrealizedGains_8389a611-d87b-4e19-9243-bed3bf29329b" xlink:href="aeri-20220630.xsd#aeri_CashAndCashEquivalentsGrossUnrealizedGains"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aeri_DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_6f958c0d-003d-41cc-b547-602e9d4f06b0" xlink:to="loc_aeri_CashAndCashEquivalentsGrossUnrealizedGains_8389a611-d87b-4e19-9243-bed3bf29329b" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30519dd8-dcba-4c1e-a866-0f59664d4182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_CashAndCashEquivalentsGrossUnrealizedGains_410eb64c-d859-48c3-b197-5636804110ef" xlink:href="aeri-20220630.xsd#aeri_CashAndCashEquivalentsGrossUnrealizedGains"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30519dd8-dcba-4c1e-a866-0f59664d4182" xlink:to="loc_aeri_CashAndCashEquivalentsGrossUnrealizedGains_410eb64c-d859-48c3-b197-5636804110ef" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13c05d1f-9cc4-4fc8-adfb-9be26c73d175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30519dd8-dcba-4c1e-a866-0f59664d4182" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13c05d1f-9cc4-4fc8-adfb-9be26c73d175" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_CashAndCashEquivalentsGrossUnrealizedLoss_fc412e5f-9429-4457-a4e3-f5fb53e80e73" xlink:href="aeri-20220630.xsd#aeri_CashAndCashEquivalentsGrossUnrealizedLoss"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30519dd8-dcba-4c1e-a866-0f59664d4182" xlink:to="loc_aeri_CashAndCashEquivalentsGrossUnrealizedLoss_fc412e5f-9429-4457-a4e3-f5fb53e80e73" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/FairValueMeasurementsFairValueMeasurementsDetails" xlink:type="simple" xlink:href="aeri-20220630.xsd#FairValueMeasurementsFairValueMeasurementsDetails"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/FairValueMeasurementsFairValueMeasurementsDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_16c30515-26e4-45dd-aa6d-1249b822f9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_680d770d-c422-478d-81d9-3333889361cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_16c30515-26e4-45dd-aa6d-1249b822f9b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_680d770d-c422-478d-81d9-3333889361cd" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a9888bd5-eab2-4a21-a831-2d450270f806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_06ad64da-7c9c-42a7-a3b7-96dbae4eb1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a9888bd5-eab2-4a21-a831-2d450270f806" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_06ad64da-7c9c-42a7-a3b7-96dbae4eb1fa" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_9791169b-305f-4663-8d9d-fef64317999b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a9888bd5-eab2-4a21-a831-2d450270f806" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_9791169b-305f-4663-8d9d-fef64317999b" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/InventoryDetails" xlink:type="simple" xlink:href="aeri-20220630.xsd#InventoryDetails"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/InventoryDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b951dd4a-35dd-48f4-9734-5b079d327b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_79f6719d-8198-476b-8444-76d40670e510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b951dd4a-35dd-48f4-9734-5b079d327b1c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_79f6719d-8198-476b-8444-76d40670e510" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f6c0a7df-2a3a-48f1-89bb-1b75d78cddcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b951dd4a-35dd-48f4-9734-5b079d327b1c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f6c0a7df-2a3a-48f1-89bb-1b75d78cddcf" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7d832066-8b4b-4523-acd0-7ee4c5c8b570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b951dd4a-35dd-48f4-9734-5b079d327b1c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7d832066-8b4b-4523-acd0-7ee4c5c8b570" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="aeri-20220630.xsd#PropertyPlantandEquipmentNetPropertyPlantandEquipmentDetails"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_82a585d8-2058-4cda-ae32-0025833ca49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7c9e1a81-d1aa-4977-8d8e-8b0f25a52dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_82a585d8-2058-4cda-ae32-0025833ca49c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7c9e1a81-d1aa-4977-8d8e-8b0f25a52dc0" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8d4c12d7-f29a-4ff1-930b-f6c5766d5ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_82a585d8-2058-4cda-ae32-0025833ca49c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8d4c12d7-f29a-4ff1-930b-f6c5766d5ec9" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="aeri-20220630.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_174149c0-d584-469f-85b4-ea1cf9aa066f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_aec0eeb6-d130-4763-9ef9-b2bb46101351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_174149c0-d584-469f-85b4-ea1cf9aa066f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_aec0eeb6-d130-4763-9ef9-b2bb46101351" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_01db098c-0da9-4ac0-af83-0334129153c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_174149c0-d584-469f-85b4-ea1cf9aa066f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_01db098c-0da9-4ac0-af83-0334129153c9" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_aeri_AccruedResearchAndDevelopmentExpenseCurrent_9fb5d376-73cb-4303-8bce-7cd3dcfa9c6e" xlink:href="aeri-20220630.xsd#aeri_AccruedResearchAndDevelopmentExpenseCurrent"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_174149c0-d584-469f-85b4-ea1cf9aa066f" xlink:to="loc_aeri_AccruedResearchAndDevelopmentExpenseCurrent_9fb5d376-73cb-4303-8bce-7cd3dcfa9c6e" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c42cb0c8-e5db-4560-aa93-52860d4a066f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_174149c0-d584-469f-85b4-ea1cf9aa066f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c42cb0c8-e5db-4560-aa93-52860d4a066f" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5b93a85-9f18-4e6f-9fec-df5255dcbf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_174149c0-d584-469f-85b4-ea1cf9aa066f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5b93a85-9f18-4e6f-9fec-df5255dcbf03" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/DebtConvertibleDebtDetails" xlink:type="simple" xlink:href="aeri-20220630.xsd#DebtConvertibleDebtDetails"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/DebtConvertibleDebtDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_ca6c14a3-efd1-47a2-ab47-5f02dc579656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_325ccfa8-24c9-4965-a48b-4a1a1ee07dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_ca6c14a3-efd1-47a2-ab47-5f02dc579656" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_325ccfa8-24c9-4965-a48b-4a1a1ee07dff" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2f55605c-95d0-4c68-8bae-3741cb727a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_ca6c14a3-efd1-47a2-ab47-5f02dc579656" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2f55605c-95d0-4c68-8bae-3741cb727a96" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b3e0e921-e825-45a4-b509-dfd140cae887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable_ca6c14a3-efd1-47a2-ab47-5f02dc579656" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b3e0e921-e825-45a4-b509-dfd140cae887" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.aeriepharma.com/role/DebtInterestExpenseofConvertibleNotesDetails" xlink:type="simple" xlink:href="aeri-20220630.xsd#DebtInterestExpenseofConvertibleNotesDetails"/>

<link:calculationLink xlink:role="http://www.aeriepharma.com/role/DebtInterestExpenseofConvertibleNotesDetails" xlink:type="extended">

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_fb343f57-625a-42cd-9786-05e58e727d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0e8bb4c4-cbef-494d-a9a7-f13f8ad93278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_fb343f57-625a-42cd-9786-05e58e727d2e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0e8bb4c4-cbef-494d-a9a7-f13f8ad93278" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_91c017fb-3922-4489-9fc5-f442b733cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_fb343f57-625a-42cd-9786-05e58e727d2e" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_91c017fb-3922-4489-9fc5-f442b733cc8f" xlink:type="arc"/>

<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_4a3768ca-edc3-4002-8688-453acab9f314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_fb343f57-625a-42cd-9786-05e58e727d2e" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_4a3768ca-edc3-4002-8688-453acab9f314" xlink:type="arc"/>

</link:calculationLink>

</link:linkbase>

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/07/22  Aerie Pharmaceuticals Inc.        DEFM14A                1:4.2M                                   Broadridge Fin’l So… Inc
 9/21/22  Aerie Pharmaceuticals Inc.        PREM14A     9/21/22    2:4.2M                                   Broadridge Fin’l So… Inc

↑Top

Filing Submission 0001337553-22-000033 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Aerie Pharmaceuticals Inc. – ‘10-Q’ for 6/30/22 – ‘EX-101.CAL’

On: Thursday, 8/4/22, at 6:35pm ET · As of: 8/5/22 · For: 6/30/22 · Accession #: 1337553-22-33 · File #: 1-36152

Previous ‘10-Q’: ‘10-Q’ on 5/6/22 for 3/31/22 · Next & Latest: ‘10-Q’ on 11/4/22 for 9/30/22 · 2 References: By: Aerie Pharmaceuticals Inc. – ‘DEFM14A’ on 10/7/22 By: Aerie Pharmaceuticals Inc. – ‘PREM14A’ on / for 9/21/22

Quarterly Report — Form 10-QFiling Table of Contents

‘EX-101.CAL’ — XBRL Calculations — aeri-20220630_cal

This Exhibit is an XBRL XML File.

2 Subsequent Filings that Reference this Filing

Previous ‘10-Q’: ‘10-Q’ on 5/6/22 for 3/31/22 · Next & Latest: ‘10-Q’ on 11/4/22 for 9/30/22 · 2 References:

Quarterly Report — Form 10-Q

Filing Table of Contents